Graft purging can translate into more durable disease remission in patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL). Currently, polymerase chain reaction (PCR) is the most widely used technique for assessment of minimal residual disease (MRD) during and after treatment. However, maximally 40-60% of the t(11;14) breakpoints or clonal immunoglobulin rearrangement in MCL can be detected using consensus PCR primers, 1, 2 and there is no worldwide standard protocol to evaluate MRD in hematopoietic stem-cell products. For exploration of a broadly sensitive assay, we conducted a retrospective study to evaluate usefulness and clinical value of flow cytometric immunophenotyping (FCM) to detect MRD in stem-cell products of FL and MCL.
Subjects were 30 patients (19 FL and 11 MCL) undergoing autologous stem-cell transplantation (ASCT) in our institute. Patient characteristics were given in Table 1 . They were diagnosed as advanced stage diseases with bone marrow/peripheral blood involvement. All patients had available FCM data before pretransplant induction chemotherapy and of stem-cell grafts.
Surface immunophenotyping of the B cells was performed using the following panel of lymphoid-associated monoclonal antibodies: fluorescein isothiocyanate/phycoerythrin/peridin chlorophyll protein yanine5.5/allophycocyanin labeled CD5 (Becton, Dickinson and Company (BD), Mountain View, CA, USA), CD10 (BD), CD19 (BD), CD20 (BD) and surface immunoglobulin (BD). Immunophenotypic detection was performed by three-color FCM. Multiparameter analysis of gated cell populations during cell suspension studies was performed to yield more definitive immunophenotypic information using CELLQuest software (BD). A total of 15 000 events were acquired in each panel. If samples contained viable cell number o15 000, the events acquired by the cytometer varied from sample to sample. For analysis, lymphocytes, monocytes and granulocytes were gated by forward vs side scatter. B lymphocytes were designated by CD19 gating in addition to forward and side scatter. Clonal B-cell expansion was detected by light chain-restricted B-cell markers. Using this method, the maximum sensitivity of FCM was 1.5 Â 10 À4 (data not shown). Figures 1a and b showed the typical examples for gating to assess lymphoma involvement. All 30 patients could obtain enough samples of stem-cell products and could be evaluated with this protocol. The negativity of tumor cell contamination (o0.01%) in grafts was confirmed in all patients.
DNA was extracted from mononuclear cells using QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions. Semi-nested PCR was carried 9 (Oki et al. 9 ) and R-ESHAP consisting of high-dose cytarabine combination regimens.
Letters to the Editor out to detect tumor cells using a GeneAmp PCR system 9700 (Life Technologies, Foster City, CA, USA). PCR method for detecting MBR/JH rearrangement was performed using primer sets LJH-P, 5 0 -TGAGGAGACGGTGACC-3 0 and MBR-P, 5 0 -CCA AGTCATGTGCATTTCCACGTC-3 0 for the first step, and VLJH-P, 5 0 -GTGACCAGGGTNCCTTGGCCCCAG-3 0 and MBR-P for the second step, as we previously described. 3 The major translocation cluster on BCL-1/JH consensus primer was used for MCL as reported by Andersen et al. 4 First, we performed semi-nested PCR using lymphoma cell lines with dilution series and found that maximum sensitivity of PCR was 1.0 Â 10 À5 . Six patients could not be tested for PCR assessment owing to lack of available primary samples. Four patients were excluded because of negative results of PCR analysis for primary samples. Finally, PCR analysis was performed in a total of 20 patients (Table 2) . Nineteen patients (14 FL and 5 MCL) had the detectable MBR/JH The 4-year estimated progression-free survival rate was 74.6% (95% CI: 39.8-91.1) and 85.7% (95% CI: 33.4-97.9) in patients with PCR-negative and -positive stem-cell products, respectively. When patients could obtain FCM-negative stem-cell products, the results of PCR analysis did not affect statistically both overall (P ¼ 0.845, Log-rank test) and progression-free survival (P ¼ 0.762, Log-rank test).
Letters to the Editor rearrangement. Three MCL patients had the t(11;14) breakpoints detected by PCR, two of which could be evaluated with both the t(11;14) breakpoints and MBR/JH rearrangement.
A total of seven patients experienced relapses. Table 3 showed the patterns of relapses after ASCT. One patient (UPN 1) with PCR-positive graft showed disease progression 3 months after ASCT. The patient received further therapy and achieved complete remission (CR). However, 4 years later after ASCT, the patient was diagnosed with secondary myelodysplastic syndromes and died in CR. Two patients with PCR-negative grafts (UPN 6 and 7) had disease progression after ASCT. Although they underwent further treatment, the primary disease had proceeded. At a median follow-up of 4 years (range, 0.3-15.1 years), the 4-year estimated overall and progression-free survival rates were 81.7% (95% CI: 61.4-92.0) and 70.5% (95% CI: 49.1-84.2), respectively in all 30 patients (Figures 1c and d) . When patients obtained FCM-negative stem-cell products, PCR results did not statistically affect both overall and progression-free survival (Figures 1e and f) .
FL and MCL are mature B-cell neoplasms characterized by the t(14;18)(q32;q21) and t(11;14)(q13;q32) translocation. Both diseases have been considered incurable with current chemotherapy regimens. High-dose chemotherapy followed by ASCT can bring some proportion of patients to a prolongation of remission duration. 2, 3, 5 One of the most conceivable factors, which lead to eventual relapses, is reinfusion of contaminating hematopoietic stem-cell grafts by tumor cells. Although there are contradictory data on graft purging, 5 our previous study 3 and other groups 2, 6 showed a clinical benefit of graft purging. To improve clinical outcomes by successful purging, appropriate evaluation for MRD is thought to be important.
Currently, PCR method is the most widely used technique for assessment of MRD. PCR primers are usually designed to target either disease characteristic translocation or patient-specific clonal immunoglobulin rearrangements in MCL and FL. In this study, MRD detection rates in grafts were 87.5% and 75% in patients with FL and MCL, respectively. PCR is a sensitive and reliable method for assessment of MRD; however, 440% of MCL cannot be detected using consensus PCR primers.
1,2 To optimize patient care, exploration of a more broadly sensitive assay would be required. 
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Bö ttcher et al. 7 reported that the sensitivity of multiparameter FCM is comparable to that of the immunoglobulin heavy chain gene (IGH)-PCR at initial staging in patients with MCL. It can be also used for MRD monitoring with a sensitivity limit of 10
À5 for leukemic B-cell chronic lymphoproliferative disorders. 8 In this study, the maximum sensitivity of FCM was 1.5 Â 10
À4
and all patients could be evaluated with FCM. When FCMnegative stem-cell products were confirmed, PCR status in grafts did not affect treatment outcome in this population. These results suggested that FCM may be a sufficient condition to evaluate MRD in grafts of FL and MCL. However, because this study has several limitations including relatively small number of samples, a retrospective study design and non-uniform highdose conditioning regimens, further studies would be needed to confirm our results.
In conclusion, this study demonstrated that for patients receiving FCM-negative stem-cell products, the results of PCR analysis for stem-cell products are not associated with treatment outcome. FCM is a cost-effective and widely used method. FCM could be a reliable analysis enough to detect MRD in stem-cell products of FL and MCL, which may be interchangeable with PCR analysis. Our results would warrant the further investigation of FCM to evaluate MRD in stem-cell products.
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